Routine SEBI dematerialisation compliance certificate for Sep 2026 quarter
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Oxygenta Pharmaceutical has submitted a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 September 2026. The company's Registrar and Transfer Agent, Venture Capital and Corporate Investments, confirmed that all share certificates received for dematerialisation were properly cancelled and the company records were updated with NSDL and CDSL as registered owner within 15 days. This is a standard quarterly procedural filing required by SEBI.
No material impact on shareholders. This is a routine regulatory compliance filing with no bearing on operations, financials, or share price.